[Form 4] BELITE BIO, INC Insider Trading Activity

Rhea-AI Filing Summary

Belite Bio director and CEO Yu-Hsin Lin reported a vesting-related stock option event tied to performance goals. On March 31, 2026, one of the performance criteria for a previously granted option was met, causing an additional 206,954 ordinary shares subject to the option to vest at an exercise price of $0.4386 per share.

This award was originally granted on December 23, 2020 and vests in installments upon meeting specific performance conditions. Following this vesting event, Lin holds options covering a total of 413,908 ordinary shares, all at the same exercise price, as part of compensation rather than an open-market trade.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Lin Yu-Hsin

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	206,954	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 413,908 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lin Yu-Hsin

(Last) (First) (Middle)

12750 HIGH BLUFF DRIVE, SUITE 475

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BELITE BIO, INC [ BLTE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.4386	03/31/2026		A		206,954		03/31/2026	12/22/2030	Ordinary Shares	206,954	$0	413,908(1)	D

Explanation of Responses:

1. On December 23, 2020, the reporting person was granted an option which shall vest in installments upon satisfaction of certain performance criteria. 206,954 ordinary shares subject to the option that had previously vested remain exercisable. One of the performance criteria was met on 3/31/2026, resulting in vesting of the option as to additional 206,954 ordinary shares.

	/s/ Yu-Hsin Lin	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Belite Bio (BLTE) disclose for Yu-Hsin Lin?

Belite Bio reported that CEO and director Yu-Hsin Lin received a vesting-related stock option for 206,954 ordinary shares. This reflects performance-based vesting of a previously granted option, not an open-market share purchase or sale, and is part of long-term equity compensation.

How many Belite Bio (BLTE) shares are covered by Yu-Hsin Lin’s vested option?

After the most recent vesting event, Yu-Hsin Lin’s option covers 413,908 ordinary shares. The filing notes that 206,954 shares had vested earlier and remained exercisable, with an additional 206,954 shares vesting once a performance criterion was met on March 31, 2026.

What is the exercise price of Yu-Hsin Lin’s Belite Bio (BLTE) stock option?

The stock option granted to Yu-Hsin Lin has an exercise price of $0.4386 per ordinary share. This price applies to all 413,908 ordinary shares subject to the option, which vest in tranches contingent on meeting specified performance criteria set at the time of the 2020 grant.

Is the Belite Bio (BLTE) Form 4 a buy or sell transaction?

The Form 4 reflects an acquisition of derivative securities via a grant/award, not a buy or sell in the market. It records performance-based vesting of an existing stock option, increasing the number of shares currently exercisable by 206,954 ordinary shares for the company’s CEO.

When was the Belite Bio (BLTE) CEO’s stock option originally granted?

The CEO’s stock option was originally granted on December 23, 2020. The option was structured to vest in installments upon satisfying certain performance criteria, with portions vesting over time as those goals are met, including the additional vesting triggered on March 31, 2026.

What triggered the latest vesting of Belite Bio (BLTE) stock options for Yu-Hsin Lin?

The latest vesting was triggered when one of the predefined performance criteria was met on March 31, 2026. As a result, an additional 206,954 ordinary shares under the previously granted option became vested and exercisable, aligning the CEO’s compensation with performance milestones.